(VRNA) – Press Releases
-
Andrew Fisher Joins Verona Pharma as General Counsel
-
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
-
Michael Austwick Joins Verona Pharma as Non-Executive Director
-
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
-
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
-
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
-
Ligand Reports Third Quarter 2023 Financial Results
-
Verona Pharma Announces November 2023 Investor Conference Participation
-
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
-
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
-
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
-
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
-
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
-
Christina Ackermann Joins Verona Pharma as Non-Executive Director
-
Ligand Reports Second Quarter 2023 Financial Results
-
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
-
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
-
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine
-
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
-
Verona Pharma to Present at Jefferies Healthcare Conference
-
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
-
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
-
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
-
Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")
-
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
-
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
-
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
-
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
-
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
-
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Ligand Reports Third Quarter 2022 Financial Results
-
Verona Pharma Announces November 2022 Investor Conference Participation
-
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
-
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
-
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
-
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Verona Pharma strengthens commercialization leadership team
-
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
-
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
-
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
-
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
-
Verona Pharma plc Announces Proposed Underwritten Public Offering
-
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Back to VRNA Stock Lookup
